$245M Verdict Deals Guardant Financial Blow

A Delaware federal court finalized a $245.2 million judgment against Guardant Health (GH) on August 21, upholding a 2023 jury finding that the liquid-biopsy company willfully infringed DNA sequencing patents that cover roughly 90% of its revenue base.

The ruling locks in royalty obligations that will drain cash from Guardant's flagship products until March 2033, raising material questions about margin sustainability for a company that has yet to reach consistent profitability.

Key Takeaways

• Final judgment totals $245.2 million, including damages, royalties, and interest.
• A 6% royalty applies to 11 Guardant products through March 2033.
• Infringing products represent ~90% of Guardant's revenue during the infringement period.

Deal Terms & Valuation Impact

The judgment breaks down into four components: $83.4 million in original damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties, and $22.9 million in pre- and post-judgment interest 1. Going forward, the court-ordered 6% royalty on U.S. sales of 11 products represents a recurring above-the-line cost that did not previously appear in Guardant's financial model.

For context, Guardant operates in the high-growth liquid-biopsy segment alongside peers such as Exact Sciences and Illumina. A perpetual 6% royalty burden on the majority of its commercial portfolio is an unusual structural headwind for a sector where gross-margin expansion is a key investment thesis.

Products in the Crosshairs

The affected portfolio includes Guardant360 CDx-the company's FDA-approved comprehensive genomic profiling blood test-as well as Guardant Reveal, used for detecting minimal residual disease, and the Shield colorectal cancer screening test 1. Several additional cancer testing and genomics services sold by Guardant are also covered by the ruling.

TwinStrand said the covered products and services accounted for approximately 90% of Guardant's revenue during the infringement period, underscoring how central the disputed technology is to Guardant's commercial engine.

Background on the Patents

The patents in dispute cover TwinStrand Biosciences' Duplex Sequencing technology, which was developed at the University of Washington and is designed to detect rare genetic mutations with greater accuracy than conventional DNA sequencing methods 1. The technology has applications across cancer research, clinical diagnostics, and pharmaceutical drug development.

A jury originally found willful infringement in November 2023. Guardant subsequently sought to overturn that verdict or secure a new trial; the Delaware district court rejected both efforts before entering final judgment on August 21, 2026.

Management & Plaintiff Response

"This verdict validates the transformative nature of Duplex Sequencing and the years of investment the University of Washington and TwinStrand have made in developing this technology," TwinStrand said in announcing the final judgment.

Guardant had not issued a public statement on the final judgment as of publication time. The company retains the option to appeal to the U.S. Court of Appeals for the Federal Circuit, which handles patent matters, though any appeal would not automatically stay the royalty obligation.

Sector Implications

The case signals that foundational sequencing-method patents carry significant commercial leverage in the liquid-biopsy market, where multiple companies rely on error-correction technologies to achieve the sensitivity needed for early cancer detection. Investors in competing diagnostics platforms may see renewed scrutiny of their own IP licensing arrangements.

With royalties running through March 2033, Guardant faces roughly seven years of incremental cost on its highest-volume products-a timeline that overlaps with the company's stated path toward profitability and the anticipated ramp of the Shield screening test.

Conclusion

The $245.2 million judgment, combined with a mandatory 6% royalty tied to nearly all of Guardant's commercial revenue, represents one of the larger patent-damages outcomes in the genomics sector in recent years. Investors will be watching closely for Guardant's next earnings call for guidance on how management plans to absorb the royalty burden and whether an appeal is forthcoming.

Not investment advice. For informational purposes only.